|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 39/395 | |
| A61K 48/00 | |||
| C07K 16/18 |
| (11) | Number of the document | 2978451 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14722916.5 |
| Date of filing the European patent application | 2014-03-28 | |
| (97) | Date of publication of the European application | 2016-02-03 |
| (45) | Date of publication and mention of the grant of the patent | 2019-11-27 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2014/032209 |
| Date | 2014-03-28 |
| (87) | Number | WO 2014/160958 |
| Date | 2014-10-02 |
| (30) | Number | Date | Country code |
| 201361806687 P | 2013-03-29 | US |
| (72) |
HUNTER, Jeffrey, W., US
TAMBURINI, Paul, P., US
|
| (73) |
Alexion Pharmaceuticals, Inc.,
121 Seaport Boulevard, Boston, MA 02210,
US
|
| (54) | COMPOSITIONS AND METHODS FOR INCREASING THE SERUM HALF-LIFE OF A THERAPEUTIC AGENT TARGETING COMPLEMENT C5 |
| COMPOSITIONS AND METHODS FOR INCREASING THE SERUM HALF-LIFE OF A THERAPEUTIC AGENT TARGETING COMPLEMENT C5 |